Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its ...
Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.03 which represents a decrease of $-1.16 or -1.36% from the prior close of $85.19. The stock opened at $85.62 and touched a low of $83 ...
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
Elon Musk's leaked texts show the response he had to boss of $1,700,000,000,000 fund when he invited him over for dinner.